• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Aerie launches Ph3 trial for Roclatan eye drug in Europe

September 6, 2017 By Sarah Faulkner

AerieAerie Pharmaceuticals (NSDQ:AERI) said today that it launched its European Mercury 3 late-stage trial of Roclatan in patients with open-angle glaucoma or ocular hypertension.

The eye drug is a fixed dose combination of Aerie’s Rhopressa netarsudil ophthalmic solution and a widely-used prostaglandin analogue, latanoprost. The company’s Phase III trial was designed to support regulatory approval and commercialization in Europe, Aerie said.

The 500-patient, six-month safety trial also includes a 90-day interim efficacy readout, the company reported, comparing once-daily Roclatan for non-inferiority to Ganfort – a fixed dose therapy sold in Europe designed to lower intraocular pressure.

Aerie said it has finished all Phase III registration study activity required for a new drug application for Roclatan in the U.S. and that it plans to submit the NDA in the first half of next year.

“This is the beginning of a new chapter for Aerie as we start our first Phase III clinical trial in Europe. We are pleased to have commenced Mercury 3 on schedule, and we currently expect to read out topline 90-day efficacy data for the trial by early 2019. As we continue to expand our global reach we also look forward to commencing our Rhopressa clinical program designed to address the Japanese market, scheduled to begin later in 2017,” chairman & CEO Vicente Anido, Jr., said in prepared remarks.

In July, Aerie touted 12-month safety data from the U.S.-based Phase III registration trial of its Roclatan eye drops.

Safety data for the 12-month study period were consistent with results observed during the 90-day efficacy period in the Mercury 1 trial. Aerie reported that there were no new adverse events that developed following the initial 90-day period.

The most common adverse event was eye redness, which was reported in 60% of patients.

Intraocular pressure was also measured throughout the 12-month study period, Aerie said, and Roclatan lowered IOP better than latanoprost and Aerie’s Rhopressa – consistent with results observed in the initial 90-day study period.

See the best minds in medtech live at DeviceTalks Boston on Oct. 2. 

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Aerie Pharmaceuticals

IN CASE YOU MISSED IT

  • Senseonics opens $50M public offering, $25M private placement with Abbott
  • Study links Abbott CGM use to lower risk of hospitalizations due to heart complications
  • Go-Pen ApS wins FDA nod for user-filled insulin pen
  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS